Logo image of XXII

22ND CENTURY GROUP INC (XXII) Stock Fundamental Analysis

NASDAQ:XXII - Nasdaq - US90137F4000 - Common Stock - Currency: USD

1.4  +0.4 (+39.3%)

Premarket: 1.35 -0.05 (-3.57%)

Fundamental Rating

2

XXII gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 8 industry peers in the Tobacco industry. XXII may be in some trouble as it scores bad on both profitability and health. XXII is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XXII has reported negative net income.
XXII had a negative operating cash flow in the past year.
XXII had negative earnings in each of the past 5 years.
XXII had a negative operating cash flow in each of the past 5 years.
XXII Yearly Net Income VS EBIT VS OCF VS FCFXXII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

XXII's Return On Assets of -117.51% is on the low side compared to the rest of the industry. XXII is outperformed by 87.50% of its industry peers.
The Return On Equity of XXII (-634.77%) is worse than 62.50% of its industry peers.
Industry RankSector Rank
ROA -117.51%
ROE -634.77%
ROIC N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXII Yearly ROA, ROE, ROICXXII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

XXII does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXII Yearly Profit, Operating, Gross MarginsXXII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

XXII does not have a ROIC to compare to the WACC, probably because it is not profitable.
XXII has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, XXII has more shares outstanding
Compared to 1 year ago, XXII has an improved debt to assets ratio.
XXII Yearly Shares OutstandingXXII Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
XXII Yearly Total Debt VS Total AssetsXXII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

XXII has an Altman-Z score of -26.24. This is a bad value and indicates that XXII is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of XXII (-26.24) is worse than 75.00% of its industry peers.
XXII has a Debt/Equity ratio of 1.29. This is a high value indicating a heavy dependency on external financing.
XXII's Debt to Equity ratio of 1.29 is in line compared to the rest of the industry. XXII outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Altman-Z -26.24
ROIC/WACCN/A
WACC6.59%
XXII Yearly LT Debt VS Equity VS FCFXXII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

XXII has a Current Ratio of 1.16. This is a normal value and indicates that XXII is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.16, XXII is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
XXII has a Quick Ratio of 1.16. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.95, XXII is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 0.95
XXII Yearly Current Assets VS Current LiabilitesXXII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

XXII shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.80%, which is quite impressive.
Looking at the last year, XXII shows a very negative growth in Revenue. The Revenue has decreased by -24.29% in the last year.
The Revenue has been decreasing by -1.15% on average over the past years.
EPS 1Y (TTM)96.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.21%
Revenue 1Y (TTM)-24.29%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-63.83%

3.2 Future

The Earnings Per Share is expected to grow by 44.03% on average over the next years. This is a very strong growth
XXII is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.06% yearly.
EPS Next Y89.2%
EPS Next 2Y44.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-15%
Revenue Next 2Y24.06%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XXII Yearly Revenue VS EstimatesXXII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
XXII Yearly EPS VS EstimatesXXII Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 0 -5K -10K -15K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XXII. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XXII. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XXII Price Earnings VS Forward Price EarningsXXII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XXII Per share dataXXII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300 -400 -500

4.3 Compensation for Growth

XXII's earnings are expected to grow with 44.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.03%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XXII!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

22ND CENTURY GROUP INC

NASDAQ:XXII (5/5/2025, 8:00:02 PM)

Premarket: 1.35 -0.05 (-3.57%)

1.4

+0.4 (+39.3%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)05-13 2025-05-13
Inst Owners10.28%
Inst Owner Change-77.13%
Ins Owners2.98%
Ins Owner Change0.49%
Market Cap3.32M
Analysts82.86
Price Target12.24 (774.29%)
Short Float %47.94%
Short Ratio1.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-43.81%
Min Revenue beat(2)-55.74%
Max Revenue beat(2)-31.87%
Revenue beat(4)0
Avg Revenue beat(4)-38.54%
Min Revenue beat(4)-61.52%
Max Revenue beat(4)-5.03%
Revenue beat(8)1
Avg Revenue beat(8)-24.25%
Revenue beat(12)2
Avg Revenue beat(12)-23.88%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.69%
PT rev (3m)-98.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)85.91%
Revenue NQ rev (1m)-38.16%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-17.87%
Revenue NY rev (3m)-17.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-526.02
EYN/A
EPS(NY)-2.19
Fwd EYN/A
FCF(TTM)-6.12
FCFYN/A
OCF(TTM)-6.05
OCFYN/A
SpS10.29
BVpS1.69
TBVpS-0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.51%
ROE -634.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.13
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.05%
Cap/Sales 0.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 0.95
Altman-Z -26.24
F-Score5
WACC6.59%
ROIC/WACCN/A
Cap/Depr(3y)104.4%
Cap/Depr(5y)87.56%
Cap/Sales(3y)9.68%
Cap/Sales(5y)6.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.21%
EPS Next Y89.2%
EPS Next 2Y44.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-24.29%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-63.83%
Revenue Next Year-15%
Revenue Next 2Y24.06%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year87.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y76.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.91%
OCF growth 3YN/A
OCF growth 5YN/A